Physician profile
Paul Smith
NPI 1568464006
$7,438.84
in general payments reported to CMS, 2019-2025
41 companies · $541 in 2025
The $541 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,845 · 2020: $700 · 2021: $964 · 2022: $1,883 · 2023: $1,506 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,941 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,941.04 |
| Education | $106.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,573.46 | 2019-2023 | Fasenra, Tagrisso, Breztri |
| Glaxosmithkline, LLC. | $1,099.93 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $901.86 | 2019-2023 | Ofev, Stiolto Respimat |
| Grifols USA, LLC | $482.76 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Jazz Pharmaceuticals INC. | $348.80 | 2019-2023 | |
| Genzyme Corporation | $332.50 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $289.98 | 2019-2023 | Dupixent |
| Mallinckrodt Hospital Products INC. | $272.82 | 2021-2023 | Acthar |
| Mylan Specialty L.P. | $265.60 | 2019-2023 | Yupelri |
| Intuitive Surgical, INC. | $250.16 | 2022-2025 | |
| Pulmonx Corporation | $168.45 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| La Jolla Pharmaceutical Company | $147.64 | 2020-2023 | Giapreza |
| Inari Medical, INC. | $137.73 | 2022 | |
| Edwards Lifesciences Corporation | $130.26 | 2019 | |
| Inspire Medical Systems, INC. | $120.00 | 2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.